Mifepristone

ADAMEVE.COM ASKS "DO YOU BELIEVE OVER-THE-COUNTER ABORTION PILLS SHOULD BE LEGALLY AVAILABLE TO WOMEN IN THE UNITED STATES?"

Retrieved on: 
Tuesday, February 6, 2024
Multimedia, LMFT, Marketing, Mifepristone, Planned Parenthood, Condom, Human, Abortion, Adam and Eve, Doctor of Philosophy, Parenthood, CST, Woman, Birth control

This month, the company surveyed over 1000 people asking if over-the-counter abortion pills should be legally available to women in the U.S. And the responses may surprise you.

Key Points: 
  • This month, the company surveyed over 1000 people asking if over-the-counter abortion pills should be legally available to women in the U.S. And the responses may surprise you.
  • Currently available only from a doctor, nurse, health clinic or Planned Parenthood, the mifepristone and/or misoprostol pills cause an "at-home abortion" that is considered both safe and effective.
  • While just over 49% of those surveyed felt that over-the-counter abortion pills should be legally available to women under any circumstance, another 24% said they should be available under certain circumstance.
  • Nearly 20% of respondents said abortion pills should not be legally available, and an additional 7% said they weren't sure.

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Retrieved on: 
Friday, January 5, 2024
Orange Book, Teva, Syndrome, FDA, The Orange Book, Therapy, Cushing's syndrome, Mifepristone, Type, Corcept Therapeutics, Teva Pharmaceuticals, Patient, Prediabetes, Generic drug

WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.

Key Points: 
  • WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.
  • On December 29, 2023, the district court held that Teva does not infringe the two patents asserted at trial, finding that Corcept had failed to show that direct infringement is likely or that Teva's label would induce infringement.
  • Teva Pharmaceuticals USA, Inc. is a leading manufacturer of generic and proprietary drug products.
  • Corcept Therapeutics, Inc., the holder of the Korlym NDA, filed a Hatch-Waxman lawsuit against Teva alleging infringement of two patents listed in the Orange Book for Korlym.

FRC's Statement Regarding Newly Released CDC Abortion Data

Retrieved on: 
Wednesday, November 22, 2023
Dignity, Woman, Risk, Supreme court, Multimedia, Family Research Council, Abortion, Health, Child, CDC, Mifepristone, Museum of Tolerance Jerusalem, Life, Birth control

WASHINGTON, Nov. 22, 2023 /PRNewswire/ -- Today, the Centers for Disease Control and Prevention (CDC) released new data showing abortions increased by five percent between 2020-2021.

Key Points: 
  • WASHINGTON, Nov. 22, 2023 /PRNewswire/ -- Today, the Centers for Disease Control and Prevention (CDC) released new data showing abortions increased by five percent between 2020-2021.
  • Family Research Council's Director of the Center for Human Dignity, Mary Szoch, released the following statement in reaction:
    "From 2020-2021, the number of abortions increased by five percent.
  • Additionally, this data shows that 56 percent of abortions occurred using the dangerous chemical abortion drug, mifepristone.
  • The CDC data shows that six women and 625,978 unborn babies lost their lives from legal and induced abortion.

Choix Closes Virtual Doors and Launches Partnership with carafem

Retrieved on: 
Monday, October 30, 2023
Technology, Women, Other Technology, Telecommunications, Telemedicine, Virtual Medicine, Other Health, General Health, Pharmaceutical, Consumer, Health, Mifepristone, Health care, Face, Research, Growth, Politics, Partnership, Moment, Medicaid, Patient satisfaction, Public, Woman, Safety, Flexible, Patient, Birth control, Nursing, Femtech

Choix garnered exceptionally high patient satisfaction rates, with over 98% surveyed expressing their willingness to recommend Choix to a friend.

Key Points: 
  • Choix garnered exceptionally high patient satisfaction rates, with over 98% surveyed expressing their willingness to recommend Choix to a friend.
  • As part of its transition and ongoing commitment to reproductive healthcare, Choix is delighted to announce its partnership with the esteemed team at carafem , offering its patients a referral to a trusted reproductive healthcare provider.
  • "carafem is a leader in modern, convenient, and professional abortion care, as well as in all aspects of sexual and reproductive healthcare," says Cindy Adam, CEO of Choix .
  • Melissa Grant, Chief Operating Officer of carafem adds, "We are thrilled to join forces with Choix in our shared commitment to delivering exceptional reproductive healthcare.

Danco Statement on Filing of Cert Petition, September 8, 2023

Retrieved on: 
Friday, September 8, 2023
REMS, Pregnancy, Fifth Circuit Four, Reproductive rights, Bleeding, Allergy, Medication, Diarrhea, Internal bleeding, Pharmacy, Mifepristone, IUD, Gestational age, Misoprostol, Health care, Fever, Danco, Weakness, Woman, Prescription, Angioedema, Prostaglandin, Hypovolemic shock, Patient, Abdominal pain, Sepsis, Rash, Tachycardia, Vomiting, Leukocytosis, Administration, Death, Syncope, Vaginal bleeding, Dizziness, Fungal infection, United States Court of Appeals for the Fifth Circuit, Anaphylaxis, Anemia, Supreme court, Law of the United Kingdom, Nausea, Court, Genetically modified bacteria, FDA, Headache, Hematocrit, Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio, Safety, Full, Pharmaceutical industry, Birth control, Vaccine, Dentistry, Nursing, Infection

Danco remains confident in the safety and effectiveness of Mifeprex® under the 2023 REMS that currently governs its use.

Key Points: 
  • Danco remains confident in the safety and effectiveness of Mifeprex® under the 2023 REMS that currently governs its use.
  • The changes in 2016 and 2021—approved by FDA after careful analysis—have expanded the availability and use of Mifeprex®, providing crucial individual and public health benefits.
  • Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following MIFEPREX use.
  • The frequency of adverse reactions varies between studies and may be dependent on many factors including the patient population and gestational age.

Danco Statement on 5th Circuit Ruling, August 16, 2023

Retrieved on: 
Thursday, August 17, 2023
REMS, Pregnancy, Reproductive rights, Bleeding, Allergy, Medication, Diarrhea, Internal bleeding, Pharmacy, Mifepristone, IUD, Gestational age, Misoprostol, Health care, Fever, Danco, Weakness, Woman, Prescription, Multimedia, Prostaglandin, Angioedema, Hypovolemic shock, Patient, Abdominal pain, Sepsis, Rash, Tachycardia, Tablet, Vomiting, Leukocytosis, Congress, Death, Administration, Syncope, Vaginal bleeding, Dizziness, United States Court of Appeals for the Fifth Circuit, Fungal infection, Anaphylaxis, Anemia, Supreme court, Nausea, Genetically modified bacteria, FDA, Headache, Hematocrit, Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio, Safety, Full, Birth control, Pharmaceutical industry, Vaccine, Dentistry, Nursing, Infection

NEW YORK, Aug. 16, 2023 /PRNewswire/ -- The Fifth Circuit panel's decision is inconsistent with established Supreme Court principles governing standing and administrative law challenges.

Key Points: 
  • NEW YORK, Aug. 16, 2023 /PRNewswire/ -- The Fifth Circuit panel's decision is inconsistent with established Supreme Court principles governing standing and administrative law challenges.
  • Danco remains confident in the safety and effectiveness of Mifeprex® and committed to making the drug available as broadly as possible.
  • Danco will continue to be at the forefront of this fight, working closely with the reproductive rights community and pharmaceutical industry, as this case moves forward.
  • Over 5 million women have used Mifeprex® in the United States since its approval for the termination of early pregnancy in 2000.

Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™

Retrieved on: 
Tuesday, July 18, 2023
Biotechnology, Practice Management, Health, General Health, Women, Oncology, Other Science, Research, Consumer, Science, Clinical Trials, Zeta, Therapeutic index, Clinical trial, Cancer, TSOI, Medicine, Cell, Immunotherapy, Protein, Patent, Mifepristone, Patient, Immune system, Potyvirus, Breast cancer, Vaccine, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today that its breast cancer focused immuno-oncology subsidiary, Res Nova Bio, Inc., has identified and filed a patent on a novel mechanism of action of its immunotherapy-enhancing product FloraStilbene™.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today that its breast cancer focused immuno-oncology subsidiary, Res Nova Bio, Inc., has identified and filed a patent on a novel mechanism of action of its immunotherapy-enhancing product FloraStilbene™.
  • Breast cancer patients with higher levels of T cell receptor zeta chain have been reported to possess superior survival as compared to patients with lower levels2.
  • “Breast cancer takes an incredible toll on patients, which I have witnessed firsthand,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor on the patent.
  • “Overcoming systemic immune defects induced by the cancer seems to us to be the first step in the optimization of immunotherapy.

New survey from All In Together finds abortion is a top voting issue heading into the election; most voters support abortion being legal

Retrieved on: 
Tuesday, June 20, 2023
Gun, Democrat, Woman, Anger, Abortion, Congress, Mifepristone, Supreme court, Motivation, Law of the United Kingdom, Republican, Drug, Birth control

NEW YORK, June 20, 2023 /PRNewswire/ -- A year after the landmark "Dobbs versus Jackson" decision was handed down by the Supreme Court, a new poll finds that women across the country - including a sizeable number of Republican women - say they were "angry" and "disappointed" by the decision. The findings come from a survey conducted by All In Together, the national, nonpartisan nonprofit in conjunction with pollster Echelon Insights.

Key Points: 
  • The findings come from a survey conducted by All In Together, the national, nonpartisan nonprofit in conjunction with pollster Echelon Insights.
  • "Abortion access is so important to Democratic women that 54% said it was a dealbreaker when it came to supporting candidates."
  • Women generally support abortion being legal in most cases, although with some restrictions.
  • The survey also oversampled 421 women with a 4.1 margin of error for a total of 1277 respondents surveyed.

Arguments in Chemical Abortion Case Could Create Friction With Pro-Lifers

Retrieved on: 
Saturday, May 20, 2023
Circuit court, FBI, Society, Chemical substance, FDA, Birth control, Mifepristone

RALEIGH, N.C., May 19, 2023 /PRNewswire-PRWeb/ -- On Wednesday, May 17, the U.S. 5th Circuit Court of Appeals is scheduled to hear arguments regarding the FDA's illegal approval and subsequent deregulation of the lethal chemical abortion drug, Mifepristone. However, pro-life strategists are concerned the case could result from a response by the pro-abortion community, such as took place in March when arguments were heard at the 5th Circuit U.S. District Court. This was when a pro-life medical network in New York, CompassCare, was vandalized a second time. CompassCare CEO, Rev. Jim Harden, notified the FBI of concerns that the case would reignite a stir from the pro-abortion community.

Key Points: 
  • CompassCare CEO Jim Harden voices concerns over the forthcoming arguments in the FDA's case.
  • RALEIGH, N.C., May 19, 2023 /PRNewswire-PRWeb/ -- On Wednesday, May 17, the U.S. 5th Circuit Court of Appeals is scheduled to hear arguments regarding the FDA's illegal approval and subsequent deregulation of the lethal chemical abortion drug, Mifepristone.
  • However, pro-life strategists are concerned the case could result from a response by the pro-abortion community, such as took place in March when arguments were heard at the 5th Circuit U.S. District Court.
  • Chemical abortion now represents over half of all abortion in the U.S. Overturning the FDA's Clinton-era, fast-track approval of the drug would cut abortion in half overnight.

Public advisory - Unauthorized drugs for abortion and emergency contraception sold illegally on "Dr. Pooja" websites

Retrieved on: 
Tuesday, May 16, 2023
Infection, DIN, Pregnancy, Asthma, Mifepristone, Pharmacy, Misoprostol, Health Canada, Medical abortion, Levonorgestrel, Coagulopathy, Uterus, Sale, Plasma protein binding, Abortion, NPN, Patient, Risk, Allergy, Drug identification number, Natural product, Birth, Health, Safety, Birth control, Dietary supplement

Health Canada is aware (link available in French only) of two "Dr. Pooja" websites ( https://www.drpoojaclinic.ca/ and http://drpoojacliniccynaecologist.com/ ) selling unauthorized prescription drugs for medical abortion labelled to contain mifepristone and misoprostol, and unauthorized over-the-counter drugs for emergency contraception labelled to contain levonorgestrel.

Key Points: 
  • Health Canada is aware (link available in French only) of two "Dr. Pooja" websites ( https://www.drpoojaclinic.ca/ and http://drpoojacliniccynaecologist.com/ ) selling unauthorized prescription drugs for medical abortion labelled to contain mifepristone and misoprostol, and unauthorized over-the-counter drugs for emergency contraception labelled to contain levonorgestrel.
  • Selling unauthorized health products in Canada is illegal, and Health Canada will do everything it can to stop this activity.
  • Unauthorized drugs may have no active ingredients, the wrong ingredients, or dangerous additives such as prescription drugs not listed on the label.
  • Health Canada has directed the websites to stop selling unauthorized health products and is working to have the websites removed.